Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
DCPH closed down 18.25 percent on Friday, October 19, 2018, on 5.18 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical DCPH trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 19||Volume Surge||Other||0.00%|
|Oct 19||Wide Range Bar||Range Expansion||0.00%|
|Oct 19||Wide Bands||Range Expansion||0.00%|
|Oct 19||Below Lower BB||Weakness||0.00%|
|Oct 19||Down 3 Days in a Row||Weakness||0.00%|
|Oct 19||Lower Bollinger Band Touch||Weakness||0.00%|
|Oct 19||Oversold Stochastic||Weakness||0.00%|
|Oct 18||180 Bearish Setup||Bearish Swing Setup||-18.25%|
|Oct 18||Wide Bands||Range Expansion||-18.25%|
|Oct 18||Oversold Stochastic||Weakness||-18.25%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more DCPH news...
|52 Week High||45.61|
|52 Week Low||15.15|
|200-Day Moving Average||30.6684|
|50-Day Moving Average||34.7772|
|20-Day Moving Average||32.3305|
|10-Day Moving Average||28.258|
|Average True Range||2.4248|
|Chandelier Exit (Long, 3 ATRs )||33.7256|
|Chandelier Exit (Short, 3 ATRs )||29.3244|
|Upper Bollinger Band||41.9661|
|Lower Bollinger Band||22.6949|
|Percent B (%b)||-0.02|
|MACD Signal Line||-2.054|
|Market Cap||710.65 Million|
|Num Shares||31.9 Million|
|Price-to-Earnings (P/E) Ratio||-1.39|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||29.93|
|Resistance 3 (R3)||30.71||28.93||28.65|
|Resistance 2 (R2)||28.93||26.98||28.54||28.22|
|Resistance 1 (R1)||25.60||25.78||24.71||24.82||27.80|
|Support 1 (S1)||20.49||21.87||19.60||19.71||16.72|
|Support 2 (S2)||18.71||20.67||18.32||16.30|
|Support 3 (S3)||15.38||18.71||15.87|
|Support 4 (S4)||14.60|